[go: up one dir, main page]

IS8181A - Efnablanda sem felur í sér PDE4 tálma og PDE5 tálma - Google Patents

Efnablanda sem felur í sér PDE4 tálma og PDE5 tálma

Info

Publication number
IS8181A
IS8181A IS8181A IS8181A IS8181A IS 8181 A IS8181 A IS 8181A IS 8181 A IS8181 A IS 8181A IS 8181 A IS8181 A IS 8181A IS 8181 A IS8181 A IS 8181A
Authority
IS
Iceland
Prior art keywords
inhibitors
preparation
pde5
pde4
pde4 inhibitors
Prior art date
Application number
IS8181A
Other languages
English (en)
Inventor
Dunkern Torsten
Hatzelmann Armin
Schudt Christian
Grimminger Friedrich
Ardeschir Ghofrani Hossein
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of IS8181A publication Critical patent/IS8181A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS8181A 2003-05-22 2005-12-14 Efnablanda sem felur í sér PDE4 tálma og PDE5 tálma IS8181A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011609 2003-05-22
PCT/EP2004/050869 WO2004103407A2 (en) 2003-05-22 2004-05-19 Composition comprising a pde4 inhibitor and a pde5 inhibitor

Publications (1)

Publication Number Publication Date
IS8181A true IS8181A (is) 2005-12-14

Family

ID=33462087

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8181A IS8181A (is) 2003-05-22 2005-12-14 Efnablanda sem felur í sér PDE4 tálma og PDE5 tálma

Country Status (23)

Country Link
US (3) US20060094723A1 (is)
EP (1) EP1628682B1 (is)
JP (1) JP2006528229A (is)
KR (1) KR20060012004A (is)
CN (1) CN1791429A (is)
AU (1) AU2004241749B2 (is)
BR (1) BRPI0410326A (is)
CA (1) CA2525946C (is)
CO (1) CO5660275A2 (is)
EA (1) EA012279B1 (is)
EC (1) ECSP056173A (is)
GE (1) GEP20084342B (is)
IL (1) IL171306A (is)
IS (1) IS8181A (is)
MA (1) MA27855A1 (is)
MX (1) MXPA05012302A (is)
NO (1) NO333501B1 (is)
NZ (1) NZ544040A (is)
RS (1) RS52730B (is)
TN (1) TNSN05265A1 (is)
UA (1) UA83041C2 (is)
WO (1) WO2004103407A2 (is)
ZA (1) ZA200508116B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
EP1755595A1 (en) * 2004-05-10 2007-02-28 Altana Pharma AG Use of roflumilast for the prophylaxis or treatment of emphysema
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
NZ560269A (en) * 2005-03-08 2010-12-24 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
EP2258350B1 (en) 2005-03-16 2014-12-24 Takeda GmbH Taste masked dosage form containing roflumilast
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
RS52944B (sr) * 2005-04-19 2014-02-28 Takeda Gmbh Roflumilast za lečenje pulmonarne hipertenzije
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
RS53461B (sr) 2006-07-05 2014-12-31 Takeda Gmbh Kombinacija inhibitora hmg-coa reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja
AU2007303846B2 (en) * 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
WO2010013925A2 (en) * 2008-07-31 2010-02-04 Dong-A Pharmaceutical. Co., Ltd. Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
EP2753332B1 (en) * 2011-09-09 2017-02-15 SK Chemicals Co., Ltd. Mridenafil for reducing skin wrinkles
JP6225178B2 (ja) * 2012-05-31 2017-11-01 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
US10058545B2 (en) * 2016-08-09 2018-08-28 Cipla Limited Method of treating pulmonary arterial hypertension
CN107648224A (zh) * 2017-10-31 2018-02-02 泰州中国医药城中医药研究院 一种治疗和预防心力衰竭药物及其在制药中的应用
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN108976107B (zh) * 2018-08-23 2021-03-23 南方医科大学 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230124467A1 (en) * 2020-03-03 2023-04-20 Mios Pharmaceuticals Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
PL178314B1 (pl) 1993-07-02 2000-04-28 Byk Gulden Lomberg Chem Fab Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
CN1043993C (zh) * 1994-08-29 1999-07-07 山之内制药株式会社 萘啶衍生物及其医药组合物
US6127363A (en) * 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2309332C (en) 1997-11-12 2002-12-03 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6417190B1 (en) * 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
CZ20032491A3 (cs) * 2001-02-15 2004-01-14 Altana Pharma Ag Ftalazinonpiperidinové deriváty
ES2276942T3 (es) * 2001-05-25 2007-07-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Combinacion de un inhibidor de pde4 y tiotropio o un derivado del mismo para tratar vias respiratorias obstructivas y otras enfermedades inflamatorias.
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient

Also Published As

Publication number Publication date
CA2525946C (en) 2013-01-29
CA2525946A1 (en) 2004-12-02
TNSN05265A1 (en) 2007-07-10
BRPI0410326A (pt) 2006-05-23
UA83041C2 (ru) 2008-06-10
US20120196867A1 (en) 2012-08-02
US20060094723A1 (en) 2006-05-04
EP1628682A2 (en) 2006-03-01
KR20060012004A (ko) 2006-02-06
ZA200508116B (en) 2007-01-31
US20100234382A1 (en) 2010-09-16
NO20055941L (no) 2005-12-14
RS52730B (sr) 2013-08-30
CN1791429A (zh) 2006-06-21
JP2006528229A (ja) 2006-12-14
EA200501690A1 (ru) 2006-06-30
MA27855A1 (fr) 2006-04-03
GEP20084342B (en) 2008-03-25
AU2004241749A1 (en) 2004-12-02
RS20050858A (sr) 2007-12-31
EA012279B1 (ru) 2009-08-28
CO5660275A2 (es) 2006-07-31
NZ544040A (en) 2009-03-31
NO333501B1 (no) 2013-06-24
MXPA05012302A (es) 2006-01-30
EP1628682B1 (en) 2013-09-25
ECSP056173A (es) 2006-04-19
WO2004103407A2 (en) 2004-12-02
WO2004103407A3 (en) 2005-02-17
IL171306A (en) 2013-08-29
AU2004241749B2 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
IS8181A (is) Efnablanda sem felur í sér PDE4 tálma og PDE5 tálma
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
SI1592686T1 (sl) Inhibitorji giraze in njihova uporaba
IS7434A (is) N-amínóasetýl-pýrrólídín-2-karbónítríl og notkun þeirra sem DDP-IV tálma
PL373146A1 (en) Pyridazinone-derivatives as pde4 inhibitors
IS7700A (is) Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
EP1742627A4 (en) PDE4B HEMMER AND ITS USE
TWI369354B (en) Cytokine inhibitors
PL372814A1 (en) Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
PH12012501372A1 (en) Proteasome inhibitors and methods of using the same
DE60319430D1 (de) R- und fgfr-inhibitoren
IL174010A0 (en) Cytokine inhibitors
AU2003303128A8 (en) Inhibitors and methods of use thereof
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
ZA200509700B (en) Caspase inhibitors and uses thereof
PL374598A1 (en) Caspase inhibitors and uses thereof
SI2594265T1 (sl) CA-IX specifični inhibitorji
PL363391A1 (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
HRP20130828T1 (en) Novel hydroxy-6-heroarylphenanthridines and their use as pde4 inhibitors
ZA200707086B (en) Cytokine inhibitors
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
IS8201A (is) Nikótínamíð afleiður gagnlegar sem PDE4 hindrar
IL177709A0 (en) Caspase inhibitors and uses thereof
AU2003299815A1 (en) Matriptase inhibitors and methods of use